Select a Category
Radiology & Nuclear Medicine
Rohren EM, Etchebehere EC, Araujo JC, Hobbs BP, Swanston NM, Everding M, Moody T, Macapinlac HA. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT. J Nucl Med. 2015; 56:1507-1512.
Obara P, Liu H, Wroblewski K, et al. Quantification of metabolic tumor activity and burden in patients with non-small-cell: Is manual adjustment of semi-automatic gradient-based measurements necessary? Nucl Med Commun 2015; 36(8):782-9.
Zhang G, Han D, Ma C, Lu J, Sun T, Liu T, Zhu J, Zhou J, Yin Y. Gradient-based Delineation of the Primary GTV on FLT PET in Squamous Cell Cancer of the Thoracic Esophagus and Impact on Radiotherapy Planning. Radiation Oncology 2015, 10:11.
Sridhar P, Mercier G, Tan J, Truong MT, Daly B, Subramaniam RM. FDG PET Metabolic Tumor Volume Segmentation and Pathologic Volume of Primary Human Solid Tumors. AJR Am J Roentgenol 2014; 202(5):1114-9.
Nelson AS, Faulhaber PF, Pirozzi SD, Harper JW, Piper JW. Comparison of Gradient PET Segmentation from a Multi-Modality PET/CT Measurement Tool to Gradient PET Segmentation Alone. J Nucl Med. 2014; 55 (Supplement 1):1522.
Werner-Wasik M, Nelson D, Choi W, Arai Y, Faulhaber P, Kang P, Almeida F, Xiao Y, Ohri N, Brockway K, Piper J, Nelson A. What is the Best Way to Contour Lung Tumors on PET Scans: Multi-Observer Validation of a Gradient-Based Method Using a NSCLC Digital PET Phantom. IJROBP 2012; 82(3):1164-1171.
Fogh S, Karancke J, Nelson AS, McCue P, Axelrod R, Werner-Wasik W. Pathologic Correlation of PET-CT Based Auto-Contouring for Radiation Planning in Lung Cancer. Presented at the World Conference on Lung Cancer Meeting in 2009.
Werner-Wasik M, Kang P, Choi W, Ohri N, Faulhaber P, Nelson D, Nelson A, Piper J, Shen Z, Pirozzi S. Comparison of PET Contouring Methods in Patients With Early-Stage Resected Non-Small Cell Lung Cancer (NSCLC): A Pathologic–Imaging Correlation IJROBP 2013; 87(2):S540.
Nelson AS, Werner-Wasik M, Choi W, et al. Evaluation of Gradient PET Segmentation for Total Lesion Glycolysis Compared to Thresholds and Manual Contouring. J Nucl Med. 2011; 52 (Supplement 1):2077.
PET Treatment Response
Etchebehere EC, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren EM. Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. J Nucl Med. 2015; 56:1177-1184.
Yu J, Cooley T, Truong MT, Mercier G, Subramaniam RM. Head and Neck Squamous Cell Cancers (Stages III and IV) Induction Chemotherapy Assessment: Value of FDG Volumetric Imaging Parameters. J Med Imaging Radiat Oncol 2014; 58(1):18-24.
Davison J, Mercier G, Russo G, Subramaniam RM. PET-Based Primary Tumor Volumetric Parameters and Survival of Patients with Non-Small Cell Lung Carcinoma. AJR Am J Roentgenol 2013; 200(3):635-40.
Shah B, Srivastava N, Hirsch AE, et al. Intra-Reader Reliability of FDG PET Volumetric Tumor Parameters: Effects of Primary Tumor Size and Segmentation Methods. Ann Nucl Med. 2012 Nov;26(9):707-14.
Romesser PB, Qureshi MM, Shah BA et al. Superior Prognostic Utility of Gross and Metabolic Tumor Volume Compared to Standardized Uptake Value Using PET/CT in Head and Neck Squamous Cell Carcinoma Patients Treated with Intensity Modulated Radiotherapy. Ann Nucl Med 2012; 26(7):527-34.
Dibble EH, Alvarez AC, Truong MT, et al. 18F-FDG Metabolic Tumor Volume and Total Glycolytic Activity of Oral Cavity and Oropharyngeal Squamous Cell Cancer: Adding Value to Clinical Staging. J Nucl Med 2012; 53(5):709-715.
Liao S, Penney BC, Wroblewski K, et al. Prognostic Value of Metabolic Tumor Burden on 18FFDG PET in Nonsurgical Patients with Non-Small Cell Lung Cancer. Eur J Nucl Med Mol Imaging 2012; 39(1):27-38.
Liao S, Penney BC, Zhang H, et al. Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-Cell Lung Cancer. Acad Radiol 2012; 19(1):69-77.
Morgan R, Chin BB, Lanning R. Feasibility of rapid integrated radiation therapy planning with follow-up FDG PET/CT to improve overall treatment assessment in head and neck cancer. Am J Nucl Med Mol Imaging. 2019 Feb 15;9(1):24-29.
Nelson AD, Nelson AS. MIM® for Therapy Response Evaluation. June 2018.